# CITATION REPORT List of articles citing

Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimers disease: link to brain reductions in acetylcholine

DOI: 10.3233/jad-2005-8304 Journal of Alzheimers Disease, 2005, 8, 247-68.

**Source:** https://exaly.com/paper-pdf/37943017/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
574	Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. Journal of Alzheimerrs Disease, <b>2006</b> , 9, 13-33	4.3	356
573	Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. <i>Journal of Alzheimerrs Disease</i> , <b>2006</b> , 10, 89-109	4.3	256
57²	Alois Alzheimer revisited: differences in origin of the disease carrying his name. <b>2006</b> , 113, 1645-58		23
571	Chronic gestational exposure to ethanol causes insulin and IGF resistance and impairs acetylcholine homeostasis in the brain. <b>2006</b> , 63, 2039-56		81
570	Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. <b>2006</b> , 103, 11784-9		305
569	Intranasal insulin improves memory in humans: superiority of insulin aspart. <b>2007</b> , 32, 239-43		219
568	Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer's disease. <b>2007</b> , 27, 824-31		70
567	Type 2 diabetes and Alzheimer's disease: from common pathologies to potential new therapeutics. <b>2007</b> , 1, 590-4		1
566	Long-term abnormalities in brain glucose/energy metabolism after inhibition of the neuronal insulin receptor: implication of tau-protein. <b>2007</b> , 195-202		37
565	Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. <b>2007</b> , 27, 13635-48		188
564	Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. <i>Journal of Alzheimerrs Disease</i> , <b>2007</b> , 12, 285-90	4.3	78
563	Nitric oxide synthase 3-mediated neurodegeneration after intracerebral gene delivery. <b>2007</b> , 66, 272-8	33	14
562	Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. <b>2007</b> , 7, 297-3	10	203
561	Neuropsychiatric Disorders An Integrative Approach. 2007,		4
560	Neuronal apoptosis in neurodegeneration. <b>2007</b> , 9, 1059-96		157
559	Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. <b>2007</b> , 257, 206-14		135
558	Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function role of glucose metabolism and insulin signalling. <b>2007</b> , 113, 131-41		41

557	Alcohol-induced disruption of endocrine signaling. <b>2007</b> , 31, 1269-85		58
556	Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. <b>2007</b> , 31, 1558-73		78
555	Constitutive expression and cytoplasmic compartmentalization of ATM protein in differentiated human neuron-like SH-SY5Y cells. <i>Journal of Neurochemistry</i> , <b>2007</b> , 100, 337-45	6	37
554	The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. <i>Experimental Gerontology</i> , <b>2007</b> , 42, 10-21	4.5	153
553	Indices of metabolic dysfunction and oxidative stress. <i>Neurochemical Research</i> , <b>2007</b> , 32, 717-22	4.6	21
552	Dicholine salt of succinic acid, a neuronal insulin sensitizer, ameliorates cognitive deficits in rodent models of normal aging, chronic cerebral hypoperfusion, and beta-amyloid peptide-(25-35)-induced amnesia. <b>2008</b> , 8, 1		23
551	Haplotype analysis of the IGF2-INS-TH gene cluster in Parkinson's disease. <b>2008</b> , 147B, 495-9		12
550	Insulin and insulin-like growth factor resistance in alcoholic neurodegeneration. 2008, 32, 1630-44		46
549	Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease. <i>Journal of Neurochemistry</i> , <b>2008</b> , 106, 1503-14	6	122
548	Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models. <b>2008</b> , 75, 1093-10	3	25
547	Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease. <b>2008</b> , 18, 47-54		16
546	Insulin, insulin-like growth factors and incretins: neural homeostatic regulators and treatment opportunities. <b>2008</b> , 22, 443-53		16
545	Alzheimer's disease is type 3 diabetes-evidence reviewed. <b>2008</b> , 2, 1101-13		662
544	Insulin resistance and Alzheimer's disease: molecular links & clinical implications. 2008, 5, 438-47		194
543	Alzheimer's disease, ceramide, visfatin and NAD. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2008</b> , 7, 492-8	2.6	16
542	Insulin Resistance Alzheimer's Disease: Pathophysiology and Treatment. 2008, 3,		1
541	Mechanisms underlying caloric restriction and lifespan regulation: implications for vascular aging. <b>2008</b> , 102, 519-28		182
540	Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. Journal of Alzheimerıs Disease, <b>2008</b> , 15, 29-44	4.3	113

539	Prevalence of oral mucosa lesions in diabetic patients: a preliminary study. 2008, 74, 423-8		20
538	Is there a role fordiet in cognitive rehabilitation?. 272-292		2
537	Prevalĥcia das alteralls da mucosa bucal em pacientes diablicos: estudo preliminar. <b>2008</b> , 74, 423-428		4
536	Mechanisms of ceramide-mediated neurodegeneration. <i>Journal of Alzheimeris Disease</i> , <b>2009</b> , 16, 705-14	4 4.3	53
535	Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. <i>Journal of Alzheimerrs Disease</i> , <b>2009</b> , 16, 585-99	4.3	58
534	Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. <i>Journal of Alzheimerrs Disease</i> , <b>2009</b> , 16, 715-29	4.3	103
533	Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. <b>2009</b> , 4, e7917		137
532	Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer's disease. <i>Journal of Alzheimeris Disease</i> , <b>2009</b> , 17, 817-25	4.3	64
531	Modeling sporadic Alzheimer's disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta. <i>Journal of Alzheimerrs Disease</i> , <b>2009</b> , 18, 729-50	4.3	80
530	Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. <b>2009</b> , 23, 3315-24		166
529	The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. <b>2009</b> , 6, 213-23		107
528	Coexistences of insulin signaling-related proteins and choline acetyltransferase in neurons. <b>2009</b> , 1249, 237-43		22
527	Insulin and IGF-I prevent brain atrophy and DNA loss in diabetes. <b>2009</b> , 1303, 179-94		12
526	Transcription-blocking DNA damage in aging: a mechanism for hormesis. <b>2009</b> , 31, 1347-56		25
525	Curcumin ameliorates impaired insulin/IGF signalling and memory deficit in a streptozotocin-treated rat model. <b>2009</b> , 31, 39-49		54
524	Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment. <b>2009</b> , 4, 54		56
523	Persistent transcription-blocking DNA lesions trigger somatic growth attenuation associated with longevity. <b>2009</b> , 11, 604-15		113
522	Growth Hormone and Insulin-Like Growth Factor I: Effects on the Brain. 2009, 2449-2471		5

521	(Pre)diabetes, brain aging, and cognition. 2009, 1792, 432-43		238
520	IGF-1 promotes beta-amyloid production by a secretase-independent mechanism. <b>2009</b> , 380, 111-4		25
519	Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. <b>2009</b> , 29, 9078-89		411
518	An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. Journal of Alzheimers Disease, 2009, 16, 741-61	4.3	141
517	Reduced TNF-Iand increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin. <b>2009</b> , 12, 867-72		17
516	Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. <i>Journal of Alzheimerrs Disease</i> , <b>2010</b> , 21, 967-84	4.3	68
515	Mitochondria and aging in the vascular system. <b>2010</b> , 88, 1021-7		68
514	Early limited nitrosamine exposures exacerbate high fat diet-mediated type 2 diabetes and neurodegeneration. <b>2010</b> , 10, 4		49
513	Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. <b>2010</b> , 5, 46		102
512	Ignoring the Evidence Will Not Stop the Alzheimer's Disease/Diabetes Pandemic. <i>Journal of Alzheimerrs Disease</i> , <b>2010</b> , 21, 71-73	4.3	
511	Glial vascular degeneration in CADASIL. <i>Journal of Alzheimerrs Disease</i> , <b>2010</b> , 21, 1393-402	4.3	10
510	Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimer's disease. Journal of Alzheimers Disease, <b>2010</b> , 22, 405-13	4.3	57
509	Neuronal insulin receptor substrate 2 (IRS2) expression is regulated by ZBP89 and SP1 binding to the IRS2 promoter. <b>2010</b> , 204, 199-208		9
508	Mechanisms of vascular aging: new perspectives. <b>2010</b> , 65, 1028-41		358
507	Oral administration of a GSK3 inhibitor increases brain insulin-like growth factor I levels. <b>2010</b> , 285, 17	693-70	00 29
506	Diabetes and the Brain. <b>2010</b> ,		3
505	The hypothalamus and Ecell connection in the gene-targeting era. 2010, 59, 2991-3		19
504	Aging-related gene expression in hippocampus proper compared with dentate gyrus is selectively associated with metabolic syndrome variables in rhesus monkeys. <b>2010</b> , 30, 6058-71		50

503	Dementia, stroke and migrainesome common pathological mechanisms. <b>2010</b> , 299, 55-65	17
502	Caloric Restriction and Cardiovascular Disease. <b>2010</b> , 263-277	1
501	Role of aspartyl-(asparaginyl)-Ehydroxylase mediated notch signaling in cerebellar development and function. <b>2010</b> , 6, 68	20
500	Growth hormone/insulin-like growth factor I axis in neurodegenerative diseases. <b>2010</b> , 33, 587-91	29
499	Preliminary use of insulin-like growth factor-I as a biomarker for sorting high-dose donepezil responders among Japanese patients with Alzheimer's disease. <b>2010</b> , 163, 137-42	3
498	Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. <b>2010</b> , 9, 399-417	240
497	PKC and Insulin Pathways in Memory Storage: Targets for Synaptogenesis, Anti-apoptosis, and the Treatment of AD. <b>2010</b> , 153-182	1
496	Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases. 2010,	74
495	Spatial distribution of glucose hypometabolism induced by intracerebroventricular streptozotocin in monkeys. <i>Journal of Alzheimeris Disease</i> , <b>2011</b> , 25, 517-23	33
494	Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease?. <b>2011</b> , 10, 264-73	161
493	IGF-I gene variability is associated with an increased risk for AD. <b>2011</b> , 32, 556.e3-11	33
492	Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. <b>2011</b> , 60, 910-20	196
491	Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/mTOR and Rac1 signaling pathways. <b>2011</b> , 61, 867-79	135
490	The Albligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. <b>2011</b> , 96, 529-43	314
489	Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. <b>2011</b> , 96, 432-42	137
488	Reprint of: 'Brain insulin signaling: A key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes'. <b>2011</b> , 96, 517-28	15
487	Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function. <b>2011</b> , 7, 1822-7	111
486	Omega-3 polyunsaturated fatty acids in the brain: metabolism and neuroprotection. <b>2011</b> , 16, 2653-70	59

485	A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. <b>2011</b> , 7, 10-8	54	
484	Knowing me, knowing you: can a knowledge of risk factors for Alzheimer's disease prove useful in understanding the pathogenesis of Parkinson's disease?. <i>Journal of Alzheimeris Disease</i> , <b>2011</b> , 25, 395-415 <sup>3</sup>	3 22	
483	Insulin resistance and pathological brain ageing. <b>2011</b> , 28, 1463-75	110	
482	Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?. <b>2011</b> , 71, 365-76	217	
481	AMP-activated protein kinase: a potential player in Alzheimer's disease. <i>Journal of Neurochemistry</i> , <b>2011</b> , 118, 460-74	148	
480	Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease. <b>2011</b> , 105, 1505-12	67	
479	Effect of pioglitazone on altered expression of Almetabolism-associated molecules in the brain of fructose-drinking rats, a rodent model of insulin resistance. <b>2011</b> , 664, 14-9	30	
478	Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease. <b>2011</b> , 1813, 965-73	88	
477	Molecular interplay between leptin, insulin-like growth factor-1, and Emyloid in organotypic slices from rabbit hippocampus. <b>2011</b> , 6, 41	29	
476	Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. <b>2011</b> , 68, 743-52	100	
475	Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer's Disease. <b>2011</b> , 9, 693-705	22	
474	Alzheimer's disease promotion by obesity: induced mechanisms-molecular links and perspectives. <b>2012</b> , 2012, 986823	43	
473	Mechanisms underlying insulin deficiency-induced acceleration of Eamyloidosis in a mouse model of Alzheimer's disease. <b>2012</b> , 7, e32792	105	
472	IRS-2 Deficiency impairs NMDA receptor-dependent long-term potentiation. <b>2012</b> , 22, 1717-27	53	
471	Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease. <i>Journal of Alzheimers Disease</i> , <b>2012</b> , 30 Suppl 2, S217-29	3 61	
470	The Role of Insulin and Insulin-Like Growth Factor-1/FoxO-Mediated Transcription for the Pathogenesis of Obesity-Associated Dementia. <b>2012</b> , 2012, 384094	14	
469	Neural stem cells in the diabetic brain. <b>2012</b> , 2012, 820790	5	
468	Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2012</b> , 11, 482-9	5 25	

467	Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. <b>2012</b> , 441, 285-96		77
466	Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. <b>2012</b> , 9, 35-66		301
465	Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. <i>Journal of Alzheimerrs Disease</i> , <b>2012</b> , 30 Suppl 2, S231-49	4.3	62
464			2
463	Role of stereotaxically injected IgG from db/db mice in the phosphorylation of the microtubule-associated protein tau in hippocampus. <b>2012</b> , 1486, 14-26		5
462	Amyloid-[protein modulates insulin signaling in presynaptic terminals. <i>Neurochemical Research</i> , <b>2012</b> , 37, 1879-85	4.6	31
461	Changes in insulin-signaling transduction pathway underlie learning/memory deficits in an Alzheimer's disease rat model. <b>2012</b> , 119, 1407-16		16
460	Psychiatric disorders presenting in the elderly with type 2 diabetes mellitus. <b>2012</b> , 20, 645-52		26
459	Different approaches, one target: understanding cellular mechanisms of Parkinson's and Alzheimer's diseases. <b>2012</b> , 34 Suppl 2, S194-205		9
458	Heat shock response and insulin-associated neurodegeneration. <b>2012</b> , 33, 129-37		12
458 457	Heat shock response and insulin-associated neurodegeneration. <b>2012</b> , 33, 129-37  Insulin in central nervous system: more than just a peripheral hormone. <b>2012</b> , 2012, 384017		12
		4.3	
457	Insulin in central nervous system: more than just a peripheral hormone. <b>2012</b> , 2012, 384017  Insulin and Alzheimer's disease: untangling the web. <i>Journal of Alzheimers Disease</i> , <b>2013</b> , 33 Suppl	4.3	170
457 456	Insulin in central nervous system: more than just a peripheral hormone. <b>2012</b> , 2012, 384017  Insulin and Alzheimer's disease: untangling the web. <i>Journal of Alzheimers Disease</i> , <b>2013</b> , 33 Suppl 1, S263-75	4.3	170 85
457 456 455	Insulin in central nervous system: more than just a peripheral hormone. <b>2012</b> , 2012, 384017  Insulin and Alzheimer's disease: untangling the web. <i>Journal of Alzheimers Disease</i> , <b>2013</b> , 33 Suppl 1, S263-75  Neurodegeneration in diabetes mellitus. <b>2012</b> , 724, 258-65  Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in	4.3	170 85 52
457 456 455 454	Insulin in central nervous system: more than just a peripheral hormone. 2012, 2012, 384017  Insulin and Alzheimer's disease: untangling the web. <i>Journal of Alzheimers Disease</i> , 2013, 33 Suppl 1, S263-75  Neurodegeneration in diabetes mellitus. 2012, 724, 258-65  Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. 2012, 72, 49-66	4.3	170 85 52 150
457 456 455 454 453	Insulin in central nervous system: more than just a peripheral hormone. 2012, 2012, 384017  Insulin and Alzheimer's disease: untangling the web. <i>Journal of Alzheimer's Disease</i> , 2013, 33 Suppl 1, S263-75  Neurodegeneration in diabetes mellitus. 2012, 724, 258-65  Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. 2012, 72, 49-66  Insulin resistance in the brain: an old-age or new-age problem?. 2012, 84, 737-45  Early and late neurodegeneration and memory disruption after intracerebroventricular	4.3	170 85 52 150

## (2013-2012)

449	disease therapeutics. <b>2012</b> , 8, 61-64	25
448	Adiponectin is protective against oxidative stress induced cytotoxicity in amyloid-beta neurotoxicity. <b>2012</b> , 7, e52354	91
447	Insulin receptor expression and activity in the brains of nondiabetic sporadic Alzheimer's disease cases. <b>2012</b> , 2012, 321280	13
446	Modulation of iron metabolism in aging and in Alzheimer's disease: relevance of the choroid plexus. <b>2012</b> , 6, 25	35
445	Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. <b>2012</b> , 4, 1582-605	35
444	Mitochondria and cardiovascular aging. <b>2012</b> , 110, 1109-24	275
443	Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. <b>2012</b> , 61, 1444-54	247
442	American ginseng improves neurocognitive function in senescence-accelerated mice: possible role of the upregulated insulin and choline acetyltransferase gene expression. <b>2012</b> , 12, 123-30	6
441	Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation. <b>2012</b> , 1441, 64-78	136
440	Alternations of central insulin-like growth factor-1 sensitivity in APP/PS1 transgenic mice and neuronal models. <b>2013</b> , 91, 717-25	20
439	Metabolic Syndrome. <b>2013</b> ,	24
438	Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. <b>2013</b> , 108, 21-43	368
437	Molecular links between Alzheimer's disease and diabetes mellitus. <b>2013</b> , 250, 140-50	132
436	Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. <b>2013</b> , 70, 972-80	70
435	Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. <b>2013</b> , 27, 505-14	329
434	Hippocampal calcium dysregulation at the nexus of diabetes and brain aging. <b>2013</b> , 719, 34-43	22
433	Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. <i>Journal of Alzheimeris Disease</i> , <b>2013</b> , 4.3 35, 789-97	141
432	Insulin, cognition, and dementia. <b>2013</b> , 719, 170-179	132

The Janus Face of Insulin in Brain. 2013, 85-113

430	Cognitive dysfunction: an emerging concept of a new diabetic complication in the elderly. <b>2013</b> , 13, 28-34	42
429	Insulin receptor signaling mediates APP processing and Emyloid accumulation without altering survival in a transgenic mouse model of Alzheimer's disease. <b>2013</b> , 35, 83-101	49
428	Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. <b>2013</b> , 38, 1729-37	51
427	When aging-onset diabetes is coming across with Alzheimer disease: comparable pathogenesis and therapy. <i>Experimental Gerontology</i> , <b>2013</b> , 48, 744-50	22
426	Protection against the synaptic targeting and toxicity of Alzheimer's-associated Albligomers by insulin mimetic chiro-inositols. <b>2013</b> , 27, 199-207	37
425	Overlapped metabolic and therapeutic links between Alzheimer and diabetes. <i>Molecular Neurobiology</i> , <b>2013</b> , 47, 399-424	60
424	Atorvastatin and pitavastatin reduce oxidative stress and improve IR/LDL-R signals in Alzheimer's disease. <b>2013</b> , 35, 193-205	24
423	Insulin and the Brain. <b>2013</b> , 9, 102-116	7
422	Cinnamon counteracts the negative effects of a high fat/high fructose diet on behavior, brain insulin signaling and Alzheimer-associated changes. <b>2013</b> , 8, e83243	46
421	Studies on Alzheimer's Disease. <b>2013</b> ,	
420	Insulin Resistance and Metabolic Failure Underlie Alzheimer Disease. <b>2013</b> , 1-30	2
419	Insulin/IGF signaling-related gene expression in the brain of a sporadic Alzheimer's disease monkey model induced by intracerebroventricular injection of streptozotocin. <i>Journal of Alzheimeris Disease</i> , <b>2014</b> , 38, 251-67	35
418	In Vivo Evidence of the Convergence of Type 2 Diabetes and Alzheimer Disease. <b>2013</b> , 395-407	
417	Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art. <b>2013</b> , 10, 1699-709	51
416	AlDeposition, Insulin Signaling, and Tau Phosphorylation in Animal Models of Alzheimer Disease and Diabetes. <b>2013</b> , 383-394	
415	CSF and Brain Indices of Insulin Resistance, Oxidative Stress and Neuro-Inflammation in Early versus Late Alzheimer's Disease. <b>2013</b> , 3, 128	25
414	Adiponectin as a new paradigm for approaching Alzheimer's disease. <b>2013</b> , 46, 229-34	31

413	Selection of appropriate reference genes for RT-qPCR analysis in a streptozotocin-induced Alzheimer's disease model of cynomolgus monkeys (Macaca fascicularis). <b>2013</b> , 8, e56034	10
412	Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: shortand long-term modification by non-genetic risk factors. <i>Frontiers in Aging Neuroscience</i> , <b>2013</b> , 5, 64	44
411	Type 2 diabetes as a risk factor for cognitive impairment: current insights. <b>2014</b> , 9, 1011-9	95
410	Meditation as a therapeutic intervention for adults at risk for Alzheimer's disease - potential benefits and underlying mechanisms. <b>2014</b> , 5, 40	43
409	Chronic cerebral hypoperfusion causes decrease of O-GlcNAcylation, hyperphosphorylation of tau and behavioral deficits in mice. <i>Frontiers in Aging Neuroscience</i> , <b>2014</b> , 6, 10	59
408	Association between risk factors for vascular dementia and adiponectin. <b>2014</b> , 2014, 261672	33
407	Brain alterations and clinical symptoms of dementia in diabetes: a/tau-dependent and independent mechanisms. <b>2014</b> , 5, 143	33
406	Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice. <b>2014</b> , 6, 1246-62	84
405	Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. <b>2014</b> , 20, 1394-8	47
404	Impaired insulin signaling and mechanisms of memory loss. <b>2014</b> , 121, 413-49	31
403	Current challenges to overcome in the management of type 2 diabetes mellitus and associated neurological disorders. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2014</b> , 13, 1440-57	6
402	Retardation of fetal dendritic development induced by gestational hyperglycemia is associated with brain insulin/IGF-I signals. <b>2014</b> , 37, 15-20	17
401	Insulin resistance, neuroinflammation, and Alzheimer's disease. <b>2014</b> , 25, 509-25	39
400	Glaucomadiabetes of the brain: a radical hypothesis about its nature and pathogenesis. <b>2014</b> , 82, 535-46	7
399	Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer's disease. <b>2014</b> , 2, 12	80
398	Neuropathology of type 2 diabetes: a short review on insulin-related mechanisms. <b>2014</b> , 24, 1961-6	7
397	The paradox of neuronal insulin action and resistance in the development of aging-associated diseases. <b>2014</b> , 10, S3-11	54
396	Effect of naringenin on brain insulin signaling and cognitive functions in ICV-STZ induced dementia model of rats. <b>2014</b> , 35, 741-51	49

395	Brain metabolic dysfunction at the core of Alzheimer's disease. <b>2014</b> , 88, 548-59	283
394	Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. <b>2014</b> , 35, 793-801	97
393	Alzheimer disease and cognitive impairment associated with diabetes mellitus type 2: associations and a hypothesis. <b>2014</b> , 29, 567-572	4
392	Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. <b>2014</b> , 128, 679-89	127
391	Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs. <b>2014</b> , 4, 31-40	59
390	Intracranial injection of PEG-PEI/ROCK II-siRNA improves cognitive impairment in a mouse model of Alzheimer's disease. <b>2014</b> , 124, 697-703	20
389	Diabetes and neurodegeneration in the brain. <b>2014</b> , 126, 489-511	28
388	Insulin resistance in Alzheimer's disease. <b>2014,</b> 72 Pt A, 92-103	78
387	Hyperglycemia induces memory impairment linked to increased acetylcholinesterase activity in zebrafish (Danio rerio). <b>2014</b> , 274, 319-25	53
386	Cardiovascular risk factors and frontotemporal dementia: a case-control study. <b>2014</b> , 3, 13	22
385	Myeloid-specific deletion of SIRT1 increases hepatic steatosis and hypothalamic inflammation in mice fed a high-fat diet. <b>2014</b> , 29, 635-43	11
384	Relationships between diabetes and cognitive impairment. <b>2014</b> , 43, 245-67	54
383	Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. <b>2014</b> , 1842, 1693-706	230
382	Type 3 diabetes is sporadic Alzheimer?s disease: mini-review. <b>2014</b> , 24, 1954-60	198
381	Deregulation of brain insulin signaling in Alzheimer's disease. <b>2014</b> , 30, 282-94	58
380	The proline-rich hypothalamic peptide is a modulator of functions of neurotrophins and neuronal activity in amyloid-induced neurodegeneration. <b>2014</b> , 8, 47-57	5
379	Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study. <b>2014</b> , 14, 64	34
378	Alzheimer disease and cognitive impairment associated with diabetes mellitus type 2: associations and a hypothesis. <b>2014</b> , 29, 567-72	21

377	Expression and possible role of IGF-IR in the mouse gastric myenteric plexus and smooth muscles. <b>2014</b> , 116, 788-94		4
376	Insulin and insulin-like growth factor receptors in the brain: physiological and pathological aspects. <b>2014</b> , 24, 1947-53		109
375	The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease. <b>2014</b> , 10, S12-25		87
374	Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology. <b>2014</b> , 35, 1233-42		60
373	Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. <b>2014</b> , 82, 1613-9		116
372	Central Nervous System Delivery of Intranasal Insulin: Mechanisms of Uptake and Effects on Cognition. <i>Journal of Alzheimeris Disease</i> , <b>2015</b> , 47, 715-28	4.3	78
371	Characterization of Cerebral Damage in a Monkey Model of Alzheimer's Disease Induced by Intracerebroventricular Injection of Streptozotocin. <i>Journal of Alzheimerrs Disease</i> , <b>2015</b> , 46, 989-1005	4.3	27
370	Tobacco Smoke Exposure Impairs Brain Insulin/IGF Signaling: Potential Co-Factor Role in Neurodegeneration. <i>Journal of Alzheimerrs Disease</i> , <b>2016</b> , 50, 373-86	4.3	21
369	Tobacco Smoke-Induced Brain White Matter Myelin Dysfunction: Potential Co-Factor Role of Smoking in Neurodegeneration. <i>Journal of Alzheimerrs Disease</i> , <b>2016</b> , 50, 133-48	4.3	24
368	Decreased Serum IGF-1/IGFBP-3 Molar Ratio is Associated with Executive Function Behaviors in Type 2 Diabetic Patients with Mild Cognitive Impairment. <i>Journal of Alzheimeris Disease</i> , <b>2015</b> , 47, 85-94	14.3	2
367	Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease. <i>Journal of Alzheimerrs Disease</i> , <b>2015</b> , 48, 637-46	4.3	22
366	The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease. <b>2015</b> , 8, 82		30
365	Association between insulin and executive functioning in alcohol dependence: a pilot study. <b>2015</b> , 11, 2903-8		1
364	Mechanisms linking brain insulin resistance to Alzheimer's disease. <b>2015</b> , 9, 96-102		26
363	Effect of a Novel Polyherbal Formulation on Diabetes Induced Memory Deficits in Rats. 2015, 05,		
362	Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment. <b>2015</b> , 6, 282-99		75
361	Aberrant insulin signaling in Alzheimer's disease: current knowledge. <b>2015</b> , 9, 204		178
360	Insulin Regulates the Activity of the High-Affinity Choline Transporter CHT. <b>2015</b> , 10, e0132934		7

359	Unaltered Prion Pathogenesis in a Mouse Model of High-Fat Diet-Induced Insulin Resistance. <b>2015</b> , 10, e0144983	12
358	Inflammation and Oxidative Stress: The Molecular Connectivity between Insulin Resistance, Obesity, and Alzheimer's Disease. <b>2015</b> , 2015, 105828	263
357	Assessment of the therapeutic potential of hesperidin and proteomic resolution of diabetes-mediated neuronal fluctuations expediting Alzheimer disease. <b>2015</b> , 5, 46965-46980	8
356	Insulin resistance in Alzheimer disease: Is heme oxygenase-1 an Achille's heel?. <b>2015</b> , 84, 69-77	24
355	Clinical development of curcumin in neurodegenerative disease. <b>2015</b> , 15, 629-37	115
354	Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer's Disease Pathology through Amyloid-IClearance. <b>2015</b> , 35, 11500-13	86
353	Whole-food diet worsened cognitive dysfunction in an Alzheimer's disease mouse model. <b>2015</b> , 36, 90-9	11
352	How to Stabilize Both the Proteins and the Membranes: Diverse Effects of sHsps in Neuroprotection. <b>2015</b> , 527-562	3
351	Synergistic effects of Emyloid and ceramide-induced insulin resistance on mitochondrial metabolism in neuronal cells. <b>2015</b> , 1852, 1810-23	11
350	Quantitative expression analysis of APP pathway and tau phosphorylation-related genes in the ICV STZ-induced non-human primate model of sporadic Alzheimer's disease. <i>International Journal of 6.3 Molecular Sciences</i> , <b>2015</b> , 16, 2386-402	15
349	The role of type 2 diabetes in neurodegeneration. <b>2015</b> , 84, 22-38	163
348	Growth factor treatment to overcome Alzheimer's dysfunctional signaling. <b>2015</b> , 27, 1025-38	23
347	Minireview: Food for thought: regulation of synaptic function by metabolic hormones. <b>2015</b> , 29, 3-13	23
346	Nanoparticle-mediated growth factor delivery systems: A new way to treat Alzheimer's disease. <b>2015</b> , 206, 187-205	52
345	Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment. <b>2015</b> , 10, 549-60	144
344	Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain. <b>2015</b> , 35, 5851-9	79
343	Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease. <b>2015</b> , 5, 425-43	19
342	Differential Contributions of Alcohol and the Nicotine-Derived Nitrosamine Ketone (NNK) to Insulin and Insulin-Like Growth Factor Resistance in the Adolescent Rat Brain. <b>2015</b> , 50, 670-9	17

341	Linking insulin with Alzheimer's disease: emergence as type III diabetes. <b>2015</b> , 36, 1763-9	3	7
340	The Aging Heart. <b>2015</b> , 5, a025148	9	19
339	Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease: studies in animal models. <b>2015</b> , 31, 1-13	4	-7
338	Role of insulin resistance in Alzheimer's disease. <b>2015</b> , 30, 839-51	2	.6
337	Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice. <b>2015</b> , 122, 593-606	4	.1
336	Diabetes augments cognitive dysfunction in chronic cerebral hypoperfusion by increasing neuronal cell death: implication of cilostazol for diabetes mellitus-induced dementia. <b>2015</b> , 73, 12-23	5	1
335	Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and in vitro models. <b>2015</b> , 36, 1221.e15-28	3	3
334	"White Paper" meeting summary and catalyst for future inquiry: Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction. <b>2016</b> , 5, 353	5	3
333	Diabetes mellitus and cognitive impairments. <b>2016</b> , 7, 412-22	1	21
332	Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies. <b>2016</b> , 6,	2	4
331	Alzheimer's Disease: From Animal Models to the Human Syndrome. <b>2016</b> ,	C	)
330	The Rationale for Insulin Therapy in Alzheimer's Disease. <b>2016</b> , 21,	1	1
329	Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer's Disease. <b>2016</b> , 11, e0155733	2	.8
328	Neuroenergetics of traumatic brain injury. <b>2016</b> , 1, CNC9	6	í
327	Traumatic brain injury and obesity induce persistent central insulin resistance. <b>2016</b> , 43, 1034-43	2	.5
326	T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. <i>Journal of Alzheimerrs Disease</i> , <b>2016</b> , 51, 123-38	2	.9
325	Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer's Disease. <i>Journal of Alzheimers Disease</i> , <b>2017</b> , 55, 849-864	4	-5
324	Cigarette Smoke-Induced Alterations in Frontal White Matter Lipid Profiles Demonstrated by MALDI-Imaging Mass Spectrometry: Relevance to Alzheimer's Disease. <i>Journal of Alzheimeris</i> 4.3 <i>Disease</i> , <b>2016</b> , 51, 151-63	1	6

323	A multipronged, nutritional-based strategy for managing Alzheimer's disease. <b>2016</b> , 91, 98-102	2
322	Exercise-induced neuroprotective effects on neurodegenerative diseases: the key role of trophic factors. <b>2016</b> , 16, 723-34	36
321	Relative expression of the p75 neurotrophin receptor, tyrosine receptor kinase A, and insulin receptor in SH-SY5Y neuroblastoma cells and hippocampi from Alzheimer's disease patients. <b>2016</b> , 101, 22-29	7
320	Oral inflammation and infection, and chronic medical diseases: implications for the elderly. <b>2016</b> , 72, 153-75	137
319	Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease. <b>2016</b> , 241, 1676-83	27
318	Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans. <b>2016</b> , 96, 1169-209	251
317	Effects of Meditation versus Music Listening on Perceived Stress, Mood, Sleep, and Quality of Life in Adults with Early Memory Loss: A Pilot Randomized Controlled Trial. <i>Journal of Alzheimers Disease</i> , <b>2016</b> , 52, 1277-98	52
316	Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?. <b>2016</b> , 213, 1375-85	113
315	Aberrant protein phosphorylation in Alzheimer disease brain disturbs pro-survival and cell death pathways. <b>2016</b> , 1862, 1871-82	48
314	Insulin signalling in Alzheimer's disease and diabetes: from epidemiology to molecular links. <b>2016</b> , 280, 430-442	49
313	The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease. <b>2016</b> , 36, 1305-1315	13
312	Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1. <i>Journal of Alzheimers Disease</i> , <b>2016</b> , 51, 961-77	40
311	Type 2 Diabetes, Obesity, and Risk for Dementia: Recent Insights into Brain Insulin Resistance and Hypometabolism. <b>2016</b> , 3, 293-300	3
310	Dysfunctional Sensory Modalities, Locus Coeruleus, and Basal Forebrain: Early Determinants that Promote Neuropathogenesis of Cognitive and Memory Decline and Alzheimer's Disease. <b>2016</b> , 30, 295-337	10
309	Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: A new paradigm. <b>2016</b> , 91, 127-42	74
308	Falls and Balance Impairments in Older Adults with Type 2 Diabetes: Thinking Beyond Diabetic Peripheral Neuropathy. <b>2016</b> , 40, 6-9	79
307	The Ames dwarf mutation attenuates Alzheimer's disease phenotype of APP/PS1 mice. <b>2016</b> , 40, 22-40	16
306	Cardiac Aging. <b>2016</b> , 459-494	1

305	Sex differences between APPswePS1dE9 mice in A-beta accumulation and pancreatic islet function during the development of Alzheimer's disease. <b>2016</b> , 50, 275-85		15
304	Caloric restriction improves diabetes-induced cognitive deficits by attenuating neurogranin-associated calcium signaling in high-fat diet-fed mice. <b>2016</b> , 36, 1098-110		23
303	Shared links between type 2 diabetes mellitus and Alzheimer's disease: A review. <b>2016</b> , 10, S144-9		86
302	Lipoprotein binding to anionic biopolyelectrolytes and the effect of glucose on nanoplaque formation in arteriosclerosis and Alzheimer's disease. <b>2016</b> , 232, 25-35		4
301	Diabetes and Alzheimer's disease crosstalk. <b>2016</b> , 64, 272-87		104
300	Effect of acute lipopolysaccharide-induced inflammation in intracerebroventricular-streptozotocin injected rats. <b>2016</b> , 101, 110-22		8
299	Insulin and the Brain: A Sweet Relationship With Intensive Care. 2017, 32, 48-58		14
298	Insulin-Like Growth Factor-II/Cation-Independent Mannose 6-Phosphate Receptor in Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , <b>2017</b> , 54, 2636-2658	6.2	26
297	Meditation and Music Improve Memory and Cognitive Function in Adults with Subjective Cognitive Decline: A Pilot Randomized Controlled Trial. <i>Journal of Alzheimers Disease</i> , <b>2017</b> , 56, 899-916	4.3	33
296	Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support. <b>2017</b> , 106, 94-100		90
295	Neurocognitive impairment in patients with comorbid diabetes mellitus and depression. <b>2017</b> , 1-2, 2-10		2
294	The Link between Type 2 Diabetes and Neurodegeneration: Roles for Amyloid-🏻 Amylin, and Tau Proteins. <i>Journal of Alzheimeris Disease</i> , <b>2017</b> , 59, 421-432	4.3	108
293	Insulin deprivation induces PP2A inhibition and tau hyperphosphorylation in hTau mice, a model of Alzheimer's disease-like tau pathology. <b>2017</b> , 7, 46359		40
292	Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease. <b>2017</b> , 82, 23-34		9
291	The Mechanisms of Action of Curcumin in Alzheimer's Disease. <i>Journal of Alzheimeris Disease</i> , <b>2017</b> , 58, 1003-1016	4.3	116
290	The behavioral deficits and cognitive impairment are correlated with decreased IGF-II and ERK in depressed mice induced by chronic unpredictable stress. <b>2017</b> , 127, 1096-1103		6
289	Molecular Interaction of Anti-Diabetic Drugs With Acetylcholinesterase and Sodium Glucose Co-Transporter 2. <b>2017</b> , 118, 3855-3865		11
288	Associations of polymorphisms in the candidate genes for Alzheimer's disease BIN1, CLU, CR1 and PICALM with gestational diabetes and impaired glucose tolerance. <b>2017</b> , 44, 227-231		6

287	A microfluidic paper-based device to assess acetylcholinesterase activity. 2017, 38, 1002-1006	15
286	Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease. <b>2017</b> , 77, 47-65	144
285	Low serum insulin-like growth factor-I (IGF-I) level is associated with increased risk of vascular dementia. <b>2017</b> , 86, 169-175	13
284	Obesity and Brain Function. <b>2017</b> ,	1
283	Impaired insulin/IGF-1 is responsible for diabetic gastroparesis by damaging myenteric cholinergic neurones and interstitial cells of Cajal. <b>2017</b> , 37,	11
282	Central and peripheral circadian clocks and their role in Alzheimer's disease. <b>2017</b> , 10, 1187-1199	31
281	Tau hyperphosphorylation induces oligomeric insulin accumulation and insulin resistance in neurons. <b>2017</b> , 140, 3269-3285	48
<b>2</b> 80	Impact of morphine on the expression of insulin receptor and protein levels of insulin/IGFs in rat neural stem cells. <b>2017</b> , 660, 147-154	2
279	Manganese and the Insulin-IGF Signaling Network in Huntington's Disease and Other Neurodegenerative Disorders. <b>2017</b> , 18, 113-142	31
278	Diabesity and Brain Energy Metabolism: The Case of Alzheimer's Disease. <b>2017</b> , 19, 117-150	11
277	Recovery of hippocampal functions and modulation of muscarinic response by electroacupuncture in young diabetic rats. <b>2017</b> , 7, 9077	10
276	Transcriptional regulation of APP by apoE: To boldly go where no isoform has gone before: ApoE, APP transcription and AD: Hypothesised mechanisms and existing knowledge gaps. <b>2017</b> , 39, 1700062	7
275	DPP4 Inhibitors Can Be a Drug of Choice for Type 3 Diabetes: A Mini Review. <b>2017</b> , 32, 444-451	12
274	Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound Albligomers. <b>2017</b> , 28, 2623-2636	59
273	Alzheimer's disease and metabolic syndrome: A link from oxidative stress and inflammation to neurodegeneration. <b>2017</b> , 71, e21990	96
272	Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. <b>2017</b> , 1863, 1078-1089	257
271	Metabolic Syndrome as a Risk Factor for Alzheimer's Disease: Is Ala Crucial Factor in Both Pathologies?. <b>2017</b> , 26, 542-560	29
270	The Triangle of Death in Alzheimer's Disease Brain: The Aberrant Cross-Talk Among Energy Metabolism, Mammalian Target of Rapamycin Signaling, and Protein Homeostasis Revealed by Redox Proteomics. <b>2017</b> , 26, 364-387	82

269	Neuroprotection by aripiprazole against Emyloid-induced toxicity by P-CK2Dectivation via inhibition of GSK-3D2017, 8, 110380-110391		6	
268	Growth Hormone and Insulin-Like Growth Factor-I: Effects on the Brain. <b>2017</b> , 289-310			
267	Brain insulin signalling, glucose metabolism and females' reproductive aging: A dangerous triad in Alzheimer's disease. <b>2018</b> , 136, 223-242		26	
266	Premature hippocampus-dependent memory decline in middle-aged females of a genetic rat model of depression. <b>2018</b> , 353, 242-249		5	
265	Age-Dependent Changes to Sphingolipid Balance in the Human Hippocampus are Gender-Specific and May Sensitize to Neurodegeneration. <i>Journal of Alzheimerrs Disease</i> , <b>2018</b> , 63, 503-514	4.3	23	
264	Evidence for Compromised Insulin Signaling and Neuronal Vulnerability in Experimental Model of Sporadic Alzheimer's Disease. <i>Molecular Neurobiology</i> , <b>2018</b> , 55, 8916-8935	6.2	17	
263	Update on Vascular Cognitive Impairment Associated with Subcortical Small-Vessel Disease. Journal of Alzheimers Disease, <b>2018</b> , 62, 1417-1441	4.3	60	
262	Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. <b>2018</b> , 14, 168-181		505	
261	Synaptic plasticity modulation by circulating peptides and metaplasticity: Involvement in Alzheimer's disease. <i>Pharmacological Research</i> , <b>2018</b> , 130, 385-401	10.2	20	
260	The 20-Year Voyage Aboard the Journal of Alzheimer's Disease: Docking at 'Type 3 Diabetes', Environmental/Exposure Factors, Pathogenic Mechanisms, and Potential Treatments. <i>Journal of Alzheimerrs Disease</i> , <b>2018</b> , 62, 1381-1390	4.3	29	
259	Arsenic impairs insulin signaling in differentiated neuroblastoma SH-SY5Y cells. 2018, 66, 22-31		3	
258	A transient insulin system dysfunction in newborn rat brain followed by neonatal intracerebroventricular administration of streptozotocin could be accompanied by a labile cognitive impairment. <b>2018</b> , 132, 17-25		4	
257	Shared pathological pathways of Alzheimer's disease with specific comorbidities: current perspectives and interventions. <i>Journal of Neurochemistry</i> , <b>2018</b> , 144, 360-389	6	8	
256	Markers of microglia in post-mortem brain samples from patients with Alzheimer's disease: a systematic review. <i>Molecular Psychiatry</i> , <b>2018</b> , 23, 177-198	15.1	195	
255	Thyroid hormone improves insulin signaling and reduces the activation of neurodegenerative pathway in the hippocampus of diabetic adult male rats. <b>2018</b> , 192, 253-258		12	
254	The Role of Long Noncoding RNAs in Diabetic Alzheimer's Disease. <b>2018</b> , 7,		7	
253	Global View on Alzheimer's Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer's Disease and Diabetes Mellitus. <b>2018</b> , 15, 1277-1282		18	
252	Inflammation in the hippocampus affects IGF1 receptor signaling and contributes to neurological sequelae in rheumatoid arthritis. <b>2018</b> , 115, E12063-E12072		20	

251	Metabolic Syndrome, Brain Insulin Resistance, and Alzheimer's Disease: Thioredoxin Interacting Protein (TXNIP) and Inflammasome as Core Amplifiers. <i>Journal of Alzheimerrs Disease</i> , <b>2018</b> , 66, 857-885 4:	3 15
250	Inflammation as a central mechanism in Alzheimer's disease. <b>2018</b> , 4, 575-590	641
249	A review of brain insulin signaling in mood disorders: From biomarker to clinical target. <b>2018</b> , 92, 7-15	14
248	Longitudinal Alzheimer's Degeneration Reflects the Spatial Topography of Cholinergic Basal Forebrain Projections. <b>2018</b> , 24, 38-46	32
247	The Association of Diabetes in the Onset of Dementia in the Elderly Population. 2018, 105-115	
246	Aging and Alzheimer's disease: Comparison and associations from molecular to system level. <b>2018</b> , 17, e12802	87
245	The Role of Insulin Resistance and Signaling in Dementia. <b>2018</b> , 143-168	
244	Insulin-Like Growth Factor Binding Protein 2 Is Associated With Biomarkers of Alzheimer's Disease Pathology and Shows Differential Expression in Transgenic Mice. <b>2018</b> , 12, 476	12
243	Streptozotocin-induced Etell damage, high fat diet, and metformin administration regulate Hes3 expression in the adult mouse brain. <b>2018</b> , 8, 11335	3
242	The Therapeutic Potential of Metformin in Neurodegenerative Diseases. <b>2018</b> , 9, 400	138
241	Mechanisms of Risk Reduction in the Clinical Practice of Alzheimer's Disease Prevention. Frontiers in Aging Neuroscience, <b>2018</b> , 10, 96	3 19
241 240	F-	3 19 77
	in Aging Neuroscience, <b>2018</b> , 10, 96  Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory	
240	in Aging Neuroscience, 2018, 10, 96  Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. 2018, 12, 37  Biliverdin reductase-A impairment links brain insulin resistance with increased Alþroduction in an	77
240	in Aging Neuroscience, 2018, 10, 96  Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. 2018, 12, 37  Biliverdin reductase-A impairment links brain insulin resistance with increased Alproduction in an animal model of aging: Implications for Alzheimer disease. 2018, 1864, 3181-3194	77
<ul><li>240</li><li>239</li><li>238</li></ul>	Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. 2018, 12, 37  Biliverdin reductase-A impairment links brain insulin resistance with increased Alproduction in an animal model of aging: Implications for Alzheimer disease. 2018, 1864, 3181-3194  The Implication of the Brain Insulin Receptor in Late Onset Alzheimer's Disease Dementia. 2018, 11,  Selenothymidine protects against biochemical and behavioral alterations induced by ICV-STZ model	77 28 32
<ul><li>240</li><li>239</li><li>238</li><li>237</li></ul>	Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. 2018, 12, 37  Billiverdin reductase-A impairment links brain insulin resistance with increased Alproduction in an animal model of aging: Implications for Alzheimer disease. 2018, 1864, 3181-3194  The Implication of the Brain Insulin Receptor in Late Onset Alzheimer's Disease Dementia. 2018, 11,  Selenothymidine protects against biochemical and behavioral alterations induced by ICV-STZ model of dementia in mice. 2018, 294, 135-143	77 28 32

233	Regional mitochondrial DNA and cell-type changes in post-mortem brains of non-diabetic Alzheimer's disease are not present in diabetic Alzheimer's disease. <b>2019</b> , 9, 11386		10
232	Modifiable Risk Factors for Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , <b>2019</b> , 11, 146	5.3	73
231	Ginsenoside compound K ameliorates Alzheimer's disease in HT22 cells by adjusting energy metabolism. <b>2019</b> , 46, 5323-5332		7
230	Higher GABA concentration in the medial prefrontal cortex of Type 2 diabetes patients is associated with episodic memory dysfunction. <b>2019</b> , 40, 4287-4295		11
229	Genome-wide RNA sequencing analysis reveals that IGF-2 attenuates memory decline, oxidative stress and amyloid plaques in an Alzheimer's disease mouse model (AD) by activating the PI3K/AKT/CREB signaling pathway. <b>2019</b> , 31, 947-959		10
228	Altered Insulin Signaling in Alzheimer's Disease Brain - Special Emphasis on PI3K-Akt Pathway. <b>2019</b> , 13, 629		114
227	Insulin Inhibits A🛮 2 Aggregation and Prevents Aឋ 2-Induced Membrane Disruption. <b>2019</b> , 58, 4519-4529		8
226	Loss of insulin-like growth factor-1 signaling in astrocytes disrupts glutamate handling. <i>Journal of Neurochemistry</i> , <b>2019</b> , 151, 689-702	6	7
225	Neurocognitive impairment in type 2 diabetes mellitus. <b>2019</b> , 18, 523-534		18
224	Regulation of Memory Function by Feeding-Relevant Biological Systems: Following the Breadcrumbs to the Hippocampus. <b>2019</b> , 12, 101		22
223	Altered expression of insulin-degrading enzyme and regulator of calcineurin in the rat intracerebral streptozotocin model and human apolipoprotein E-A-associated Alzheimer's disease. <b>2019</b> , 11, 392-404		8
222	A Perspective to the Correlation Between Brain Insulin Resistance and Alzheimer: Medicinal Chemistry Approach. <b>2019</b> , 15, 255-258		2
221	A Systematic Review of MicroRNA Expression as Biomarker of Late-Onset Alzheimer's Disease. <i>Molecular Neurobiology</i> , <b>2019</b> , 56, 8376-8391	6.2	38
220	Higher Plasma Level of Nampt Presaging Memory Dysfunction in Chinese Type 2 Diabetes Patients with Mild Cognitive Impairment. <i>Journal of Alzheimeris Disease</i> , <b>2019</b> , 70, 303-314	4.3	4
219	The Role of Insulin Resistance and Protein O-GlcNAcylation in Neurodegeneration. 2019, 13, 473		13
218	Insulin and Autophagy in Neurodegeneration. <b>2019</b> , 13, 491		24
217	Contribution of astrocytes to metabolic dysfunction in the Alzheimer's disease brain. <b>2019</b> , 400, 1113-1	127	14
216	O-GlcNAcylation of Amyloid-IProtein Precursor by Insulin Signaling Reduces Amyloid-IProduction. <i>Journal of Alzheimens Disease</i> , <b>2019</b> , 69, 1195-1211	4.3	8

215	Mammalian Target of Rapamycin at the Crossroad Between Alzheimer's Disease and Diabetes. <b>2019</b> , 1128, 185-225		11	
214	The Full Spectrum of Alzheimer's Disease Is Rooted in Metabolic Derangements That Drive Type 3 Diabetes. <b>2019</b> , 1128, 45-83		21	
213	Molecular Connection Between Diabetes and Dementia. <b>2019</b> , 1128, 103-131		7	
212	Lin28B regulates the fate of grafted mesenchymal stem cells and enhances their protective effects against Alzheimer's disease by upregulating IGF-2. <b>2019</b> , 234, 21860-21876		6	
211	Diabetes Mellitus. 2019,			
210	Tortuous Paths of Insulin Signaling and Mitochondria in Alzheimer's Disease. <b>2019</b> , 1128, 161-183		3	
209	Altered Brain Expression of Insulin and Insulin-Like Growth Factors in Frontotemporal Lobar Degeneration: Another Degenerative Disease Linked to Dysregulation of Insulin Metabolic Pathways. <b>2019</b> , 11, 1759091419839515		6	
208	Comprehensive review on the interaction between natural compounds and brain receptors: Benefits and toxicity. <b>2019</b> , 174, 87-115		21	
207	Effects of pulsed electromagnetic fields on learning and memory abilities of STZ-induced dementia rats. <b>2019</b> , 38, 123-130		6	
206	Outcomes and clinical implications of intranasal insulin administration to the central nervous system. <b>2019</b> , 317, 180-190		23	
205	Revisiting the Role of Insulin-Like Growth Factor-I Receptor Stimulating Activity and the Apolipoprotein E in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , <b>2019</b> , 11, 20	5.3	17	
204	Cross-disease analysis of Alzheimer's disease and type-2 Diabetes highlights the role of autophagy in the pathophysiology of two highly comorbid diseases. <b>2019</b> , 9, 3965		41	
203	Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine. <b>2019</b> , 199, 173-187		48	
202	Vildagliptine protects SH-SY5Y human neuron-like cells from A⊞-42 induced toxicity, in vitro. <b>2019</b> , 71, 635-646		1	
201	Profiling of Alzheimer's disease related genes in mild to moderate vitamin D hypovitaminosis. <b>2019</b> , 67, 123-137		7	
200	Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease. <b>2019</b> , 125, 176	5-189	38	
199	Resistance Exercise-Induced Responses in Physiological Factors Linked with Cognitive Health. Journal of Alzheimers Disease, <b>2019</b> , 68, 39-64	4.3	17	
198	Insulin Resistance and Oxidative Stress in the Brain: What's New?. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	91	

### (2020-2019)

197	Early-Stage Alzheimer's Disease Is Associated with Simultaneous Systemic and Central Nervous System Dysregulation of Insulin-Linked Metabolic Pathways. <i>Journal of Alzheimens Disease</i> , <b>2019</b> , 68, 657-668	4.3	25
196	Focus on the Correlations between Alzheimer's Disease and Type 2 Diabetes. <b>2019</b> , 19, 571-579		10
195	Association between cognitive impairment patient with solid cancer and insulin resistance. <b>2019</b> , 12, 705		
194	Natural Compounds as Beneficial Antioxidant Agents in Neurodegenerative Disorders: A Focus on Alzheimer's Disease. <b>2019</b> , 8,		35
193	Future Treatment of Alzheimer Disease. <b>2019</b> ,		1
192	Broadening the definition of brain insulin resistance in aging and Alzheimer's disease. <b>2019</b> , 313, 79-87		22
191	Timing Matters: Circadian Effects on Energy Homeostasis and Alzheimer's Disease. <b>2019</b> , 30, 132-143		6
190	Zebrafish models of diabetes-related CNS pathogenesis. <b>2019</b> , 92, 48-58		12
189	Insulin growth factor 2 (IGF2) as an emergent target in psychiatric and neurological disorders. Review. <b>2019</b> , 149, 1-13		18
188	Effects of aging, high-fat diet, and testosterone treatment on neural and metabolic outcomes in male brown Norway rats. <b>2019</b> , 73, 145-160		11
187	The neuroprotective effect and action mechanism of polyphenols in diabetes mellitus-related cognitive dysfunction. <b>2020</b> , 59, 1295-1311		10
186	Disparate Central and Peripheral Effects of Circulating IGF-1 Deficiency on Tissue Mitochondrial Function. <i>Molecular Neurobiology</i> , <b>2020</b> , 57, 1317-1331	6.2	9
185	Roles of vascular risk factors in the pathogenesis of dementia. <b>2020</b> , 43, 162-167		14
184	Prenatal stress promotes icv-STZ-induced sporadic Alzheimer's pathology through central insulin signaling change. <b>2020</b> , 241, 117154		2
183	The Protective Effect of Exercise in Neurodegenerative Diseases: The Potential Role of Extracellular Vesicles. <i>Cells</i> , <b>2020</b> , 9,	7.9	12
182	The correlation of serum adiponectin and insulin resistance with the presence and severity of dementia in non-obese Alzheimer's patients. <b>2020</b> , 40, 376-382		2
181	The Role of Bilirubin and the Other "Yellow Players" in Neurodegenerative Diseases. 2020, 9,		3
180	Unwinding Complexities of Diabetic Alzheimer by Potent Novel Molecules. <b>2020</b> , 35, 153331752093754	2	8

179	Insulin signaling as a therapeutic target in Alzheimer disease: Efficacy of apomorphine. 2020, 8, 146-154	6
178	Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions. <b>2020</b> , 14, 670	17
177	Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones. <b>2020</b> , 155, 37-64	10
176	Clusterin as a Potential Biomarker of Obesity-Related Alzheimer's Disease Risk. <b>2020</b> , 15, 117727192096410	8 1
175	The Other Side of Alzheimer's Disease: Influence of Metabolic Disorder Features for Novel Diagnostic Biomarkers. <b>2020</b> , 10,	4
174	Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review. <b>2020</b> , 11, 560375	15
173	Patients with Alzheimer's Disease Have Increased Levels of Insulin-like Growth Factor-I in Serum but not in Cerebrospinal Fluid. <i>Journal of Alzheimeris Disease</i> , <b>2020</b> , 75, 289-298	5
172	Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 6.3 21,	13
171	Effects of low- and high-intensity physical exercise on physical and cognitive function in older persons with dementia: a randomized controlled trial. <b>2020</b> , 12, 28	18
170	Mini Review: Opposing Pathologies in Cancer and Alzheimer's Disease: Does the PI3K/Akt Pathway Provide Clues?. <b>2020</b> , 11, 403	8
169	Insulin-like growth factor 2 (IGF2) protects against Huntington's disease through the extracellular disposal of protein aggregates. <b>2020</b> , 140, 737-764	14
168	Sorting Out the Role of the in Alzheimer's Disease. <i>Journal of Alzheimerrs Disease Reports</i> , <b>2020</b> , 4, 123-1 <u>4</u> 9,	7
167	Genetic risk factors for Creutzfeldt-Jakob disease. <b>2020</b> , 142, 104973	6
166	Effect of amyloid toxicity or chronic cerebral hypoperfusion on brain insulin resistance in a rat model with intracerebroventricular streptozotocin. <b>2020</b> , 158, 40-50	3
165	Glucose signaling in the brain and periphery to memory. <b>2020</b> , 110, 100-113	6
164	ApoE and cerebral insulin: Trafficking, receptors, and resistance. <b>2020</b> , 137, 104755	20
163	Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome. <b>2020</b> , 137, 104772	23
162	Intranasal Insulin: a Treatment Strategy for Addiction. <b>2020</b> , 17, 105-115	5

# (2021-2020)

161	Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer's disease. <b>2020</b> , 81, 194-205		9
160	Interaction of opioid with insulin/IGFs signaling in Alzheimer's disease. <b>2020</b> , 70, 819-834		2
159	Islet Amyloid Polypeptide: A Partner in Crime With Alln the Pathology of Alzheimer's Disease. <b>2020</b> , 13, 35		19
158	Acteoside-improved streptozotocin-induced learning and memory impairment by upregulating hippocampal insulin, glucose transport, and energy metabolism. <b>2021</b> , 35, 392-403		5
157	Human gut microbiota Agathobaculum butyriciproducens improves cognitive impairment in LPS-induced and APP/PS1 mouse models of Alzheimer's disease. <b>2021</b> , 86, 96-108		10
156	Intranasal Insulin for Alzheimer's Disease. <b>2021</b> , 35, 21-37		19
155	Growth Hormone and Neuronal Hemoglobin in the Brain-Roles in Neuroprotection and Neurodegenerative Diseases. <b>2020</b> , 11, 606089		5
154	Cardiac aging. <b>2021</b> , 323-344		
153	Impact of Genetic Risk Factors for Alzheimer's Disease on Brain Glucose Metabolism. <i>Molecular Neurobiology</i> , <b>2021</b> , 58, 2608-2619	6.2	2
152	Suppression of neuronal cholesterol biosynthesis impairs brain functions through insulin-like growth factor I-Akt signaling. <b>2021</b> , 17, 3702-3716		1
151	Association between exenatide use and incidence of Alzheimer's disease. <b>2021</b> , 7, e12139		1
150	Insulin-Like Growth Factor 2 As a Possible Neuroprotective Agent and Memory Enhancer-Its Comparative Expression, Processing and Signaling in Mammalian CNS. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
149	Metabolic disorder in Alzheimer's disease. <b>2021</b> , 36, 781-813		3
148	Modifiable, Non-Modifiable, and Clinical Factors Associated with Progression of Alzheimer's Disease. <i>Journal of Alzheimeri</i> s <i>Disease</i> , <b>2021</b> , 80, 1-27	4.3	8
147	Intranasal administration of 40 and 80 units of insulin does not cause hypoglycemia during cardiac surgery: a randomized controlled trial. <b>2021</b> , 68, 991-999		O
146	Brain insulin, insulin-like growth factor 1 and glucagon-like peptide 1 signalling in Alzheimer's disease. <b>2021</b> , 33, e12959		9
145	Insulin resistance, oxidative stress and mitochondrial defects in Ts65dn mice brain: A harmful synergistic path in down syndrome. <b>2021</b> , 165, 152-170		16
144	Regulation of Metabolic Health by an "Olfactory-Hypothalamic Axis" and Its Possible Implications for the Development of Therapeutic Approaches for Obesity and T2D. <b>2021</b> , 1		3

143	The relationship between diabetes-related cognitive dysfunction and leukoaraiosis. <i>Acta Neurologica Belgica</i> , <b>2021</b> , 121, 1101-1110	1.5	1
142	The link between nutrition and Alzheimer's disease: from prevention to treatment. <b>2021</b> , 11, 155-166		3
141	Everolimus: A potential therapeutic agent targeting PI3K/Akt pathway in brain insulin system dysfunction and associated neurobehavioral deficits. <b>2021</b> , 35, 1018-1031		0
140	Insulin Resistance and Diabetes Mellitus in Alzheimer's Disease. <i>Cells</i> , <b>2021</b> , 10,	7.9	10
139	Insulin-Like Growth Factor-II and Ischemic Stroke-A Prospective Observational Study. 2021, 11,		
138	Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses. <i>Journal of Alzheimeris Disease</i> , <b>2021</b> , 82, 71-105	4.3	7
137	G-protein coupled receptor, PI3K and Rho signaling pathways regulate the cascades of Tau and amyloid-līn Alzheimer's disease <b>2021</b> , 2, 17		0
136	Neurotrophic signaling deficiency exacerbates environmental risks for Alzheimer's disease pathogenesis. <b>2021</b> , 118,		3
135	Role of protein tyrosine phosphatase 1B inhibitor in central insulin resistance and associated cognitive deficits. <b>2021</b> , 171, 113-125		0
134	The cerebral hypometabolism model of Alzheimer's disease explored: can a ketogenic diet improve cognition in Alzheimer's disease? A review of the literature. <b>2021</b> , 17, 95-103		
133	Brain Glucose Transporters: Role in Pathogenesis and Potential Targets for the Treatment of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
132	Insulin Resistance Exacerbates Alzheimer Disease via Multiple Mechanisms. <b>2021</b> , 15, 687157		9
131	Mitostasis, Calcium and Free Radicals in Health, Aging and Neurodegeneration. 2021, 11,		11
130	Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration. 2021, 16, 44		21
129	Associations of the Glycaemic Control of Diabetes with Dementia and Physical Function in Rural-Dwelling Older Chinese Adults: A Population-Based Study. <b>2021</b> , 16, 1503-1513		5
128	Effects of apolipoprotein E isoform, sex, and diet on insulin BBB pharmacokinetics in mice. <b>2021</b> , 11, 18636		O
127	Is resveratrol a prospective therapeutic strategy in the co-association of glucose metabolism disorders and neurodegenerative diseases?. <b>2021</b> , 1-16		1
126	Large-scale proteome analysis of CSF implicates altered glucose metabolism in Alzheimer∃ disease.		О

125	Metabolic determinants of Alzheimer's disease: A focus on thermoregulation. 2021, 72, 101462	5
124	The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. <b>2021</b> , 176, 16-33	8
123	Islet amyloid polypeptide & amyloid beta peptide roles in Alzheimer's disease: two triggers, one disease. <b>2021</b> , 16, 1127-1130	8
122	A Neonatal Mild Defect in Brain Insulin Signaling Predisposes a Subclinical Model of Sporadic Alzheimer's to Develop the Disease. <b>2021</b> , 71, 1473-1484	O
121	Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease. <b>2021</b> , 4, 193-205	O
120	Metabolic Syndrome as a Risk Factor for Alzheimer Disease. <b>2013</b> , 281-341	3
119	Brain Oxidative Stress in the Pathogenesis and Progression of Alzheimer Disease. 2013, 99-118	1
118	Insulin receptor activation by proinsulin preserves synapses and vision in retinitis pigmentosa.	1
117	Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. <b>2012</b> , 122, 1316-38	1101
116	White PaperImeeting summary and catalyst for future inquiry: Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction. <b>2016</b> , 5, 353	60
115	Cognitive dysfunctions in individuals with diabetes mellitus. <b>2019</b> , 36, 183-191	24
114	Therapeutic Advantages of Dual Targeting of PPAR-land PPAR-lin an Experimental Model of Sporadic Alzheimer's Disease. <b>2018</b> , 5,	6
113	Brain deletion of insulin receptor substrate 2 disrupts hippocampal synaptic plasticity and metaplasticity. <b>2012</b> , 7, e31124	50
112	GIT2 acts as a potential keystone protein in functional hypothalamic networks associated with age-related phenotypic changes in rats. <b>2012</b> , 7, e36975	29
111	IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice. <b>2014</b> , 9, e94287	55
110	Overexpression of the IGF-II/M6P receptor in mouse fibroblast cell lines differentially alters expression profiles of genes involved in Alzheimer's disease-related pathology. <b>2014</b> , 9, e98057	3
109	Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. <b>2017</b> , 12, e0183565	38
108	Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic	10

107	Proteomics Analysis of CA1 Region of the Hippocampus in Pre-, Progression and Pathological Stages in a Mouse Model of the Alzheimer's Disease. <b>2019</b> , 16, 613-621		4
106	The Action of Polyphenols in Diabetes Mellitus and Alzheimer's Disease: A Common Agent for Overlapping Pathologies. <b>2019</b> , 17, 590-613		19
105	A Comprehensive Review of Alzheimer's Association with Related Proteins: Pathological Role and Therapeutic Significance. <b>2020</b> , 18, 674-695		9
104	Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2014</b> , 13, 338-46	2.6	16
103	Extending Arms of Insulin Resistance from Diabetes to Alzheimer's Disease: Identification of Potential Therapeutic Targets. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2019</b> , 18, 172-184	2.6	13
102	Diabetic Cognitive Dysfunction: From Bench to Clinic. <i>Current Medicinal Chemistry</i> , <b>2020</b> , 27, 3151-3167	4.3	11
101	Dysregulation of Insulin-Linked Metabolic Pathways in Alzheimer's Disease: Co-Factor Role of Apolipoprotein E 4. <i>Journal of Alzheimerrs Disease Reports</i> , <b>2020</b> , 4, 479-493	3.3	2
100	Sweet but Bitter: Focus on Fructose Impact on Brain Function in Rodent Models. <i>Nutrients</i> , <b>2020</b> , 13,	6.7	7
99	Alzheimer's disease: Unique markers for diagnosis & new treatment modalities. <b>2015</b> , 142, 369-82		9
98	Insulin and insulin-like growth factor prevent brain atrophy and cognitive impairment in diabetic rats. <b>2012</b> , 16, S601-10		10
97	Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal. <b>2015</b> , 6, 1223-42		29
96	Insulin resistance and Alzheimer's disease. <b>2009</b> , 42, 475-81		261
95	Functional switching of ATM: sensor of DNA damage in proliferating cells and mediator of Akt survival signal in post-mitotic human neuron-like cells. <b>2012</b> , 31, 364-72		14
94	Insulin Resistance Syndrome and Alzheimer Disease. 2008, 105-120		
93	The Role of Insulin Resistance in Age-Related Cognitive Decline and Dementia. 2009, 433-457		
92	«Ageingfeatures» analysis of IGF-1 and PGC-1 genes polymorphism. <b>2009</b> , 7, 12-18		2
91	Neurochemical Aspects of Neurodegenerative Diseases. <b>2010</b> , 249-324		
90	The Relationship between the IGF System, Nutrition, and Behavior. <b>2011</b> , 259-269		

## (2021-2013)

89	Molecular Aspects of Obesity and Insulin Resistance in Metabolic Syndrome and Neurological Disorders. <b>2013</b> , 143-189		
88	Modulation of Cognition by Insulin and Aging: Implications for Alzheimer Disease. 115-135		
87	Experimental Approach to Alzheimer Disease. <b>2014</b> , 2025-2045		
86	[Diabetes mellitus and the central nervous system]. <b>2016</b> , 88, 82-86		2
85	TYPES OF DIABETES. <b>2017</b> , 10, 35-37		1
84	The Relationship between Polyneuropathy and Cognitive Functions in Type 2 Diabetes Mellitus Patients. <b>2020</b> , 54, 41-46		O
83	Medical Family Therapy in Endocrinology. <b>2018</b> , 293-319		
82	Insulin Resistance and Oligodendrocyte/Microvascular Endothelial Cell Dysfunction as Mediators of White Matter Degeneration in Alzheimer Disease. 123-145		
81	Insulin-like growth factor 2 (IGF2) protects against Huntington disease through the extracellular disposal of protein aggregates.		
80	Disentangling Mitochondria in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
79	Inflammation and insulin resistance in Alzheimer disease: partners in crime. 2020, 389-405		О
78	Metabolic Pathways Underlying Neuropsychiatric Disorders and Obesity. 2020, 415-426		
77	Mammalian target of rapamycin complexes. <b>2020</b> , 325-341		
76	POTENTIAL NON-GROWTH USES OF rhIGF-I. <b>2007</b> , 23, 1-7		2
75	Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases. <i>Panminerva Medica</i> , <b>2012</b> , 54, 171-8	2	30
74	Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. <i>Current Opinion in Investigational Drugs</i> , <b>2009</b> , 10, 1049-60		91
73	Diabetic Encephalopathy Affecting Mitochondria and Axonal Transport Proteins. <i>Basic and Clinical Neuroscience</i> , <b>2020</b> , 11, 781-793	1.4	
72	Molecular and Biochemical Pathways Encompassing Diabetes Mellitus and Dementia. CNS and Neurological Disorders - Drug Targets, 2021,	2.6	2

71	Association of Alzheimer's Disease and Insulin Resistance in King Abdulaziz Medical City, Jeddah <i>Cureus</i> , <b>2021</b> , 13, e19811	1.2	O
70	A Non-Invasive Determination of Ketosis-Induced Elimination of Chronic Daytime Somnolence in a Patient with Late-Stage Dementia (Assessed with Type 3 Diabetes): A Potential Role of Neurogenesis <i>Journal of Alzheimerrs Disease Reports</i> , <b>2021</b> , 5, 827-846	3.3	
69	iabetic Encephalopathy Affecting Mitochondria and Axonal Transport Proteins. <i>Basic and Clinical Neuroscience</i> , <b>2020</b> , 11, 781-794	1.4	0
68	Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 825816	4.6	2
67	Aqueous Ajwa dates seeds extract improves memory impairment in type-2 diabetes mellitus rats by reducing blood glucose levels and enhancing brain cholinergic transmission <i>Saudi Journal of Biological Sciences</i> , <b>2022</b> , 29, 2738-2748	4	1
66	The Effect of Type 2 Diabetes Mellitus on the Development of Alzheimer Disease and Its Molecular Mechanism. <i>Bezmilem Science</i> , <b>2022</b> , 10, 114-122	1.7	
65	Type 3 diabetes (T3D) and alzheimer∃ disease (AD). Current Trends in Pharmacy and Pharmaceutical Chemistry, <b>2022</b> , 4, 8-12		
64	Alzheimer's Disease as Type 3 Diabetes: Common Pathophysiological Mechanisms between Alzheimer's Disease and Type 2 Diabetes <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	3
63	Shared Molecular Mechanisms among Alzheimer's Disease, Neurovascular Unit Dysfunction and Vascular Risk Factors: A Narrative Review <i>Biomedicines</i> , <b>2022</b> , 10,	4.8	0
62	Occurrence of mild cognitive impairment with hyperinsulinaemia in Africans with advanced type 2 diabetes mellitus. <i>IBRO Neuroscience Reports</i> , <b>2022</b> ,		
61	Impaired insulin signalling and allostatic load in Alzheimer disease <i>Nature Reviews Neuroscience</i> , <b>2022</b> ,	13.5	8
60	Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration <i>Degenerative Neurological and Neuromuscular Disease</i> , <b>2022</b> , 12, 31-59	5.4	O
59	Sukkari dates seed improves type-2 diabetes mellitus-induced memory impairment by reducing blood glucose levels and enhancing brain cholinergic transmission: In vivo and molecular modeling studies. <i>Saudi Pharmaceutical Journal</i> , <b>2022</b> ,	4.4	4
58	Brain Metabolic Alterations in Alzheimer's Disease <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	1
57	D-galactose-induced aging in rats - The effect of metformin on bioenergetics of brain, skeletal muscle and liver <i>Experimental Gerontology</i> , <b>2022</b> , 111770	4.5	0
56	Insulin gene expression and functional activity of insulin signaling pathway in Alzheimer's disease. <i>Fundamental and Clinical Medicine</i> , <b>2021</b> , 6, 8-21	0.5	
55	In Vitro Comparative Study of Solid Lipid and PLGA Nanoparticles Designed to Facilitate Nose-to-Brain Delivery of Insulin <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
54	siRNA Mediated GSK3IKnockdown Targets Insulin Signaling Pathway and Rescues Alzheimer's Disease Pathology: Evidence from and Studies <i>ACS Applied Materials &amp; Disease Pathology</i> : Evidence from and Studies <i>ACS Applied Materials &amp; Disease Pathology</i> : Evidence from and Studies <i>ACS Applied Materials &amp; Disease</i> : Insulin Studies <i>Disease</i> : Insulin Studies <i></i>	9.5	1

37

36

Role of Reactive Astrocytes in Alzheimer Disease. 2022, 199-242 53 Insulin receptor activation by proinsulin preserves synapses and vision in retinitis pigmentosa.. Cell 9.8 52 Death and Disease, 2022, 13, 383 Image\_1.pdf. 2018, 51 50 Table\_1.DOCX. 2018, Table\_2.docx. **2018**, 49 TOR-dependent cerebrovascular aging in Alzheimer's disease.. 2014, 8, 31-38 48 Is the Brain Undernourished in Alzheimer's Disease?. Nutrients, 2022, 14, 6.7 47 О Antidiabetic Drugs in the Treatment of Alzheimer's Disease.. International Journal of Molecular 46 6.3 Sciences, 2022, 23, Brain insulin resistance and the therapeutic value of insulin and insulin-sensitizing drugs in 1.5 O 45 Alzheimer's disease neuropathology.. Acta Neurologica Belgica, 2022, 1 Docosahexaenoic acid enhances hippocampal insulin sensitivity to promote cognitive function of 13 44 aged rats on a high-fat diet. Journal of Advanced Research, 2022, Contributive Role of Hyperglycemia and Hypoglycemia Towards the Development of Alzheimer's 6.2 43 2 Disease.. Molecular Neurobiology, 2022, 1 High-fat diet-induced diabetes couples to Alzheimer's disease through inflammation-activated 42 15.1 C/EBPIAEP pathway.. Molecular Psychiatry, 2022, Down-Regulation of Insulin Like Growth Factor 1 Involved in Alzheimer's Disease via MAPK, Ras, 6.7 O 41 and FoxO Signaling Pathways.. Oxidative Medicine and Cellular Longevity, 2022, 2022, 8169981 Ubiquitin and Ubiquitin-like Proteins in Cancer, Neurodegenerative Disorders, and Heart Diseases.. 40 6.3 International Journal of Molecular Sciences, 2022, 23, Role of Biliverdin Reductase A in the Regulation of Insulin Signaling in Metabolic and 6.3 39 2 Neurodegenerative Diseases: An Update. International Journal of Molecular Sciences, 2022, 23, 5574 Exploring the Pharmacological Potential of Metformin for Neurodegenerative Diseases.. Frontiers 38 5.3 in Aging Neuroscience, 2022, 14, 838173

Insulin-Like Growth Factor, Inflammation, and MRI Markers of Alzheimer Disease in Predominantly

Diagnostic, Prognostic, and Mechanistic Biomarkers of Diabetes Mellitus-Associated Cognitive

Middle-Aged Adults. Journal of Alzheimerrs Disease, 2022, 1-12

Decline. International Journal of Molecular Sciences, 2022, 23, 6144

4.3

6.3

35	Effect of Letrozole on hippocampal Let-7 microRNAs and their correlation with working memory and phosphorylated Tau protein in an Alzheimer's disease-like rat model. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , <b>2022</b> , 58,	1.6	
34	The Role of Mitochondrial Quality Control in Cognitive Dysfunction in Diabetes. <i>Neurochemical Research</i> ,	4.6	1
33	GLP-1-Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight. <i>Cells</i> , <b>2022</b> , 11, 2023	7.9	3
32	Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs. <i>Frontiers in Aging</i> , 3,	2.5	O
31	Low Serum Insulin-like Growth Factor-I Is Associated with Decline in Hippocampal Volume in Stable Mild Cognitive Impairment but not in Alzheimer Disease. <i>Journal of Alzheimer Disease</i> , <b>2022</b> , 1-10	4.3	
30	Role of Hypertension and Hyperlipidemia in the Pathogenesis of Dementia. <b>2022</b> , 251-272		
29	Therapeutic Potential of Phytochemicals: Lessons Learned from Streptozotocin-Induced Sporadic Alzheimer Disease. <b>2022</b> , 531-553		
28	Neuroprotective potential of curcuminoids in modulating Alzheimer Disease via multiple signaling pathways. <i>Current Medicinal Chemistry</i> , <b>2022</b> , 29,	4.3	
27	Deletion of serine racemase reverses neuronal insulin signaling inhibition by amyloid-loligomers. <i>Journal of Neurochemistry</i> ,	6	O
26	Body weight variability and the risk of dementia in patients with type 2 diabetes mellitus: a nationwide cohort study in Korea. <i>Diabetes Research and Clinical Practice</i> , <b>2022</b> , 110015	7.4	
25	Reduced Hippocampal and Anterior Cingulate Expression of Antioxidant Enzymes and Membrane Progesterone Receptors in Alzheimer Disease with Depression. <i>Journal of Alzheimers Disease</i> , <b>2022</b> , 1-13	4.3	
24	Trends in insulin resistance: insights into mechanisms and therapeutic strategy. <i>Signal Transduction and Targeted Therapy</i> , <b>2022</b> , 7,	21	10
23	Inside the diabetic brain: Insulin resistance and molecular mechanism associated with cognitive impairment and its possible therapeutic strategies. <i>Pharmacological Research</i> , <b>2022</b> , 182, 106358	10.2	3
22	Adiponectin, the adiponectin paradox, and Alzheimer Disease: Is this association biologically plausible?.		1
21	Cognitive Dysfunction and Diabetes. <b>2022</b> , 23, 165-177		О
20	A Novel Ketone-Supplemented Diet Improves Recognition Memory and Hippocampal Mitochondrial Efficiency in Healthy Adult Mice. <b>2022</b> , 12, 1019		1
19	Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics. <b>2022</b> , 11, 3372		1
18	Cerebrovascular insulin receptors are defective in Alzheimer∃ disease.		1

#### CITATION REPORT

17	Impaired spatial navigation and age-dependent hippocampal synaptic dysfunction are associated with chronic inflammatory response in db/db mice.	O
16	Insulin stimulates atypical protein kinase C-mediated phosphorylation of the neuronal adaptor FE65 to potentiate neurite outgrowth by activating ARF6-Rac1 signaling. <b>2022</b> , 36,	0
15	Common and rare variants of EGF increase the genetic risk of Alzheimer's disease as revealed by targeted sequencing of growth factors in Han Chinese. <b>2022</b> ,	0
14	Effects of distinct n-6 to n-3 polyunsaturated fatty acid ratios on insulin resistant and AD-like phenotypes in high-fat diets-fed APP/PS1 mice. <b>2022</b> , 112207	O
13	Brain Insulin Resistance, Nitric Oxide and Alzheimer Disease Pathology. <b>2022</b> , 238-259	0
12	BACE2: A Promising Neuroprotective Candidate for Alzheimer Disease. <b>2022</b> , 1-13	O
11	Insulin resistance in Alzheimer⊠ Disease: the genetics and metabolomics links. 2022,	1
10	The identities of insulin signaling pathway are affected by overexpression of Tau and its phosphorylation form. 14,	O
9	Intranasal Administration of KYCCSRK Peptide Rescues Brain Insulin Signaling Activation and Reduces Alzheimer Disease-like Neuropathology in a Mouse Model for Down Syndrome. <b>2023</b> , 12, 111	1
8	Gold nanoparticle-enhanced X-ray microtomography of the rodent reveals region-specific cerebrospinal fluid circulation in the brain. <b>2023</b> , 14,	O
7	Increased Risk of Aging-Related Neurodegenerative Disease after Traumatic Brain Injury. 2023, 11, 1154	0
6	Radix Rehmanniae Praeparata (Shu Dihuang) exerts neuroprotective effects on ICV-STZ-induced Alzheimer disease mice through modulation of INSR/IRS-1/AKT/GSK-3 Isignaling pathway and intestinal microbiota. 14,	O
5	Metabolic Syndrome as a Risk Factor for Alzheimer∃ Disease: A Focus on Insulin Resistance. <b>2023</b> , 24, 4354	0
4	The Effects of Momordica charantia on Type 2 Diabetes Mellitus and Alzheimer∄ Disease. <b>2023</b> , 24, 4643	O
3	Neurotransmitters in Type 2 Diabetes and the Control of Systemic and Central Energy Balance. <b>2023</b> , 13, 384	0
2	IGF2 in memory, neurodevelopmental disorders, and neurodegenerative diseases. 2023,	O
1	Geroprotective interventions in the 3xTg mouse model of Alzheimer∃ disease.	О